Global Panic Attack Treatment Market
Global Panic Attack Treatment Market

Panic Attack Treatment Comprehensive Study by Type (Antidepressant Drugs, SSRIs, SNRIs, Benzodiazepines, Devices and Therapy, TMS, DBS, VBS), Indicators (MDD, OCD, Phobia) Players and Region - Global Market Outlook to 2025

Panic Attack Treatment Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Jan 2019 Edition 231 Pages 165 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Industry Background:
According to World Health Organization (WHO) Fact Sheet, depression is a “common illness worldwide, with more than 300 million 51 people affected. Panic attack treatment is the type of treatment for Selective serotonin reuptake inhibitors (SSRIs). Panic attack and anxiety attack are the two different attacks. Panic attacks are unprovoked and unpredictable. Yoga and deep breathing may help to reduce incidences of panic attack. There are various symptoms of panic attack such as sweating, trembling, shortness of breath, a choking sensation, chest pain, nausea, dizziness, fear of losing your mind, fear of dying, feeling hot or cold and numbness or tingling. These type of attacks are happens anywhere and anytime.This growth is primarily driven by Rising Prevalence of Depression and Panic Attacks due to Unhealthier Lifestyles and Increasing Awareness about Panic Attack Treatments.

Globally, a noticeable market trend is evident Emergence of Comparatively more Effective and Efficient Panic Attack Treatments . Major Players, such as Pfizer Inc. (United States), GlaxoSmithKline (United Kingdom), Merck & Co. Inc. (United States), Sanofi-Aventis (France), AstraZeneca (United Kingdom), Eli Lilly and Company (United States), Johnson & Johnson (United States), Abbott Laboratories (United States), F-Hoffmann-La Roche (Switzerland) and Shionogi and Company (Japan) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:
On 19th December 2018, GlaxoSmithKline Plc. (GSK) has confirmed an agreement with Pfizer Inc. to form joint venture which will combine their consumer health businesses with combined trades of around 12.7 USD billion. Pfizer will have an equity interest of 32% in the Joint Venture. On the other hand, GSK will have a majority controlling equity interest of 68%.

Regulatory Insights:
In 2004, the United States’ Food and Drug Administration (FDA) has mandated all the depression drug manufacturers to add a boxed warning to the labelling of all antidepressant medications. This labelling should warn about the rising risks of suicidal thinking or suicidal behaviour in children and adolescents taking antidepressants during initial treatment and with dose increases. Moreover, in 2007, FDA requested that the warning be extended to include young adults through age 24.

Market Drivers
  • Rising Prevalence of Depression and Panic Attacks due to Unhealthier Lifestyles
  • Increasing Awareness about Panic Attack Treatments

Market Trend
  • Emergence of Comparatively more Effective and Efficient Panic Attack Treatments
  • Growing Adoption of SSRI Antidepressants
  • Availability of Favorable Reimbursement Policies for Medications and Therapies

Restraints
  • Limited Patent Validity Timeline for Branded Depression Drugs
  • Adverse Side Effects from Panic Attack Drugs

Opportunities
Surging Technological Advancements in Mental Health Drug Development and Robust Investments in Research and Development for ongoing Drug Discovery
Challenges
Lack of Healthcare Infrastructure in Underdeveloped Countries and Complexities in International Drug Trades

AdvanceMarketAnalytics follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization of the Report:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Antidepressant Drugs
  • SSRIs
  • SNRIs
  • Benzodiazepines
  • Devices and Therapy
  • TMS
  • DBS
  • VBS
By Indicators
  • MDD
  • OCD
  • Phobia

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Prevalence of Depression and Panic Attacks due to Unhealthier Lifestyles
      • 3.2.2. Increasing Awareness about Panic Attack Treatments
    • 3.3. Market Challenges
      • 3.3.1. Lack of Healthcare Infrastructure in Underdeveloped Countries
      • 3.3.2. Complexities in International Drug Trades
    • 3.4. Market Trends
      • 3.4.1. Emergence of Comparatively more Effective and Efficient Panic Attack Treatments
      • 3.4.2. Growing Adoption of SSRI Antidepressants
      • 3.4.3. Availability of Favorable Reimbursement Policies for Medications and Therapies
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Panic Attack Treatment, by Type, Indicators and Region (value) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Panic Attack Treatment (Value)
      • 5.2.1. Global Panic Attack Treatment by: Type (Value)
        • 5.2.1.1. Antidepressant Drugs
        • 5.2.1.2. SSRIs
        • 5.2.1.3. SNRIs
        • 5.2.1.4. Benzodiazepines
        • 5.2.1.5. Devices and Therapy
        • 5.2.1.6. TMS
        • 5.2.1.7. DBS
        • 5.2.1.8. VBS
      • 5.2.2. Global Panic Attack Treatment by: Indicators (Value)
        • 5.2.2.1. MDD
        • 5.2.2.2. OCD
        • 5.2.2.3. Phobia
      • 5.2.3. Global Panic Attack Treatment Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Panic Attack Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. GlaxoSmithKline (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Merck & Co. Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Sanofi-Aventis (France)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. AstraZeneca (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Eli Lilly and Company (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Johnson & Johnson (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Abbott Laboratories (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. F-Hoffmann-La Roche (Switzerland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Shionogi and Company (Japan)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Panic Attack Treatment Sale, by Type, Indicators and Region (value) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Panic Attack Treatment (Value)
      • 7.2.1. Global Panic Attack Treatment by: Type (Value)
        • 7.2.1.1. Antidepressant Drugs
        • 7.2.1.2. SSRIs
        • 7.2.1.3. SNRIs
        • 7.2.1.4. Benzodiazepines
        • 7.2.1.5. Devices and Therapy
        • 7.2.1.6. TMS
        • 7.2.1.7. DBS
        • 7.2.1.8. VBS
      • 7.2.2. Global Panic Attack Treatment by: Indicators (Value)
        • 7.2.2.1. MDD
        • 7.2.2.2. OCD
        • 7.2.2.3. Phobia
      • 7.2.3. Global Panic Attack Treatment Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Panic Attack Treatment: by Type(USD Million)
  • Table 2. Panic Attack Treatment Antidepressant Drugs , by Region USD Million (2013-2018)
  • Table 3. Panic Attack Treatment SSRIs , by Region USD Million (2013-2018)
  • Table 4. Panic Attack Treatment SNRIs , by Region USD Million (2013-2018)
  • Table 5. Panic Attack Treatment Benzodiazepines , by Region USD Million (2013-2018)
  • Table 6. Panic Attack Treatment Devices and Therapy , by Region USD Million (2013-2018)
  • Table 7. Panic Attack Treatment TMS , by Region USD Million (2013-2018)
  • Table 8. Panic Attack Treatment DBS , by Region USD Million (2013-2018)
  • Table 9. Panic Attack Treatment VBS , by Region USD Million (2013-2018)
  • Table 10. Panic Attack Treatment: by Indicators(USD Million)
  • Table 11. Panic Attack Treatment MDD , by Region USD Million (2013-2018)
  • Table 12. Panic Attack Treatment OCD , by Region USD Million (2013-2018)
  • Table 13. Panic Attack Treatment Phobia , by Region USD Million (2013-2018)
  • Table 14. South America Panic Attack Treatment, by Country USD Million (2013-2018)
  • Table 15. South America Panic Attack Treatment, by Type USD Million (2013-2018)
  • Table 16. South America Panic Attack Treatment, by Indicators USD Million (2013-2018)
  • Table 17. Brazil Panic Attack Treatment, by Type USD Million (2013-2018)
  • Table 18. Brazil Panic Attack Treatment, by Indicators USD Million (2013-2018)
  • Table 19. Argentina Panic Attack Treatment, by Type USD Million (2013-2018)
  • Table 20. Argentina Panic Attack Treatment, by Indicators USD Million (2013-2018)
  • Table 21. Rest of South America Panic Attack Treatment, by Type USD Million (2013-2018)
  • Table 22. Rest of South America Panic Attack Treatment, by Indicators USD Million (2013-2018)
  • Table 23. Asia Pacific Panic Attack Treatment, by Country USD Million (2013-2018)
  • Table 24. Asia Pacific Panic Attack Treatment, by Type USD Million (2013-2018)
  • Table 25. Asia Pacific Panic Attack Treatment, by Indicators USD Million (2013-2018)
  • Table 26. China Panic Attack Treatment, by Type USD Million (2013-2018)
  • Table 27. China Panic Attack Treatment, by Indicators USD Million (2013-2018)
  • Table 28. Japan Panic Attack Treatment, by Type USD Million (2013-2018)
  • Table 29. Japan Panic Attack Treatment, by Indicators USD Million (2013-2018)
  • Table 30. India Panic Attack Treatment, by Type USD Million (2013-2018)
  • Table 31. India Panic Attack Treatment, by Indicators USD Million (2013-2018)
  • Table 32. South Korea Panic Attack Treatment, by Type USD Million (2013-2018)
  • Table 33. South Korea Panic Attack Treatment, by Indicators USD Million (2013-2018)
  • Table 34. Taiwan Panic Attack Treatment, by Type USD Million (2013-2018)
  • Table 35. Taiwan Panic Attack Treatment, by Indicators USD Million (2013-2018)
  • Table 36. Australia Panic Attack Treatment, by Type USD Million (2013-2018)
  • Table 37. Australia Panic Attack Treatment, by Indicators USD Million (2013-2018)
  • Table 38. Rest of Asia-Pacific Panic Attack Treatment, by Type USD Million (2013-2018)
  • Table 39. Rest of Asia-Pacific Panic Attack Treatment, by Indicators USD Million (2013-2018)
  • Table 40. Europe Panic Attack Treatment, by Country USD Million (2013-2018)
  • Table 41. Europe Panic Attack Treatment, by Type USD Million (2013-2018)
  • Table 42. Europe Panic Attack Treatment, by Indicators USD Million (2013-2018)
  • Table 43. Germany Panic Attack Treatment, by Type USD Million (2013-2018)
  • Table 44. Germany Panic Attack Treatment, by Indicators USD Million (2013-2018)
  • Table 45. France Panic Attack Treatment, by Type USD Million (2013-2018)
  • Table 46. France Panic Attack Treatment, by Indicators USD Million (2013-2018)
  • Table 47. Italy Panic Attack Treatment, by Type USD Million (2013-2018)
  • Table 48. Italy Panic Attack Treatment, by Indicators USD Million (2013-2018)
  • Table 49. United Kingdom Panic Attack Treatment, by Type USD Million (2013-2018)
  • Table 50. United Kingdom Panic Attack Treatment, by Indicators USD Million (2013-2018)
  • Table 51. Netherlands Panic Attack Treatment, by Type USD Million (2013-2018)
  • Table 52. Netherlands Panic Attack Treatment, by Indicators USD Million (2013-2018)
  • Table 53. Rest of Europe Panic Attack Treatment, by Type USD Million (2013-2018)
  • Table 54. Rest of Europe Panic Attack Treatment, by Indicators USD Million (2013-2018)
  • Table 55. MEA Panic Attack Treatment, by Country USD Million (2013-2018)
  • Table 56. MEA Panic Attack Treatment, by Type USD Million (2013-2018)
  • Table 57. MEA Panic Attack Treatment, by Indicators USD Million (2013-2018)
  • Table 58. Middle East Panic Attack Treatment, by Type USD Million (2013-2018)
  • Table 59. Middle East Panic Attack Treatment, by Indicators USD Million (2013-2018)
  • Table 60. Africa Panic Attack Treatment, by Type USD Million (2013-2018)
  • Table 61. Africa Panic Attack Treatment, by Indicators USD Million (2013-2018)
  • Table 62. North America Panic Attack Treatment, by Country USD Million (2013-2018)
  • Table 63. North America Panic Attack Treatment, by Type USD Million (2013-2018)
  • Table 64. North America Panic Attack Treatment, by Indicators USD Million (2013-2018)
  • Table 65. United States Panic Attack Treatment, by Type USD Million (2013-2018)
  • Table 66. United States Panic Attack Treatment, by Indicators USD Million (2013-2018)
  • Table 67. Canada Panic Attack Treatment, by Type USD Million (2013-2018)
  • Table 68. Canada Panic Attack Treatment, by Indicators USD Million (2013-2018)
  • Table 69. Mexico Panic Attack Treatment, by Type USD Million (2013-2018)
  • Table 70. Mexico Panic Attack Treatment, by Indicators USD Million (2013-2018)
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Company Basic Information, Sales Area and Its Competitors
  • Table 78. Company Basic Information, Sales Area and Its Competitors
  • Table 79. Company Basic Information, Sales Area and Its Competitors
  • Table 80. Company Basic Information, Sales Area and Its Competitors
  • Table 81. Panic Attack Treatment: by Type(USD Million)
  • Table 82. Panic Attack Treatment Antidepressant Drugs , by Region USD Million (2019-2024)
  • Table 83. Panic Attack Treatment SSRIs , by Region USD Million (2019-2024)
  • Table 84. Panic Attack Treatment SNRIs , by Region USD Million (2019-2024)
  • Table 85. Panic Attack Treatment Benzodiazepines , by Region USD Million (2019-2024)
  • Table 86. Panic Attack Treatment Devices and Therapy , by Region USD Million (2019-2024)
  • Table 87. Panic Attack Treatment TMS , by Region USD Million (2019-2024)
  • Table 88. Panic Attack Treatment DBS , by Region USD Million (2019-2024)
  • Table 89. Panic Attack Treatment VBS , by Region USD Million (2019-2024)
  • Table 90. Panic Attack Treatment: by Indicators(USD Million)
  • Table 91. Panic Attack Treatment MDD , by Region USD Million (2019-2024)
  • Table 92. Panic Attack Treatment OCD , by Region USD Million (2019-2024)
  • Table 93. Panic Attack Treatment Phobia , by Region USD Million (2019-2024)
  • Table 94. South America Panic Attack Treatment, by Country USD Million (2019-2024)
  • Table 95. South America Panic Attack Treatment, by Type USD Million (2019-2024)
  • Table 96. South America Panic Attack Treatment, by Indicators USD Million (2019-2024)
  • Table 97. Brazil Panic Attack Treatment, by Type USD Million (2019-2024)
  • Table 98. Brazil Panic Attack Treatment, by Indicators USD Million (2019-2024)
  • Table 99. Argentina Panic Attack Treatment, by Type USD Million (2019-2024)
  • Table 100. Argentina Panic Attack Treatment, by Indicators USD Million (2019-2024)
  • Table 101. Rest of South America Panic Attack Treatment, by Type USD Million (2019-2024)
  • Table 102. Rest of South America Panic Attack Treatment, by Indicators USD Million (2019-2024)
  • Table 103. Asia Pacific Panic Attack Treatment, by Country USD Million (2019-2024)
  • Table 104. Asia Pacific Panic Attack Treatment, by Type USD Million (2019-2024)
  • Table 105. Asia Pacific Panic Attack Treatment, by Indicators USD Million (2019-2024)
  • Table 106. China Panic Attack Treatment, by Type USD Million (2019-2024)
  • Table 107. China Panic Attack Treatment, by Indicators USD Million (2019-2024)
  • Table 108. Japan Panic Attack Treatment, by Type USD Million (2019-2024)
  • Table 109. Japan Panic Attack Treatment, by Indicators USD Million (2019-2024)
  • Table 110. India Panic Attack Treatment, by Type USD Million (2019-2024)
  • Table 111. India Panic Attack Treatment, by Indicators USD Million (2019-2024)
  • Table 112. South Korea Panic Attack Treatment, by Type USD Million (2019-2024)
  • Table 113. South Korea Panic Attack Treatment, by Indicators USD Million (2019-2024)
  • Table 114. Taiwan Panic Attack Treatment, by Type USD Million (2019-2024)
  • Table 115. Taiwan Panic Attack Treatment, by Indicators USD Million (2019-2024)
  • Table 116. Australia Panic Attack Treatment, by Type USD Million (2019-2024)
  • Table 117. Australia Panic Attack Treatment, by Indicators USD Million (2019-2024)
  • Table 118. Rest of Asia-Pacific Panic Attack Treatment, by Type USD Million (2019-2024)
  • Table 119. Rest of Asia-Pacific Panic Attack Treatment, by Indicators USD Million (2019-2024)
  • Table 120. Europe Panic Attack Treatment, by Country USD Million (2019-2024)
  • Table 121. Europe Panic Attack Treatment, by Type USD Million (2019-2024)
  • Table 122. Europe Panic Attack Treatment, by Indicators USD Million (2019-2024)
  • Table 123. Germany Panic Attack Treatment, by Type USD Million (2019-2024)
  • Table 124. Germany Panic Attack Treatment, by Indicators USD Million (2019-2024)
  • Table 125. France Panic Attack Treatment, by Type USD Million (2019-2024)
  • Table 126. France Panic Attack Treatment, by Indicators USD Million (2019-2024)
  • Table 127. Italy Panic Attack Treatment, by Type USD Million (2019-2024)
  • Table 128. Italy Panic Attack Treatment, by Indicators USD Million (2019-2024)
  • Table 129. United Kingdom Panic Attack Treatment, by Type USD Million (2019-2024)
  • Table 130. United Kingdom Panic Attack Treatment, by Indicators USD Million (2019-2024)
  • Table 131. Netherlands Panic Attack Treatment, by Type USD Million (2019-2024)
  • Table 132. Netherlands Panic Attack Treatment, by Indicators USD Million (2019-2024)
  • Table 133. Rest of Europe Panic Attack Treatment, by Type USD Million (2019-2024)
  • Table 134. Rest of Europe Panic Attack Treatment, by Indicators USD Million (2019-2024)
  • Table 135. MEA Panic Attack Treatment, by Country USD Million (2019-2024)
  • Table 136. MEA Panic Attack Treatment, by Type USD Million (2019-2024)
  • Table 137. MEA Panic Attack Treatment, by Indicators USD Million (2019-2024)
  • Table 138. Middle East Panic Attack Treatment, by Type USD Million (2019-2024)
  • Table 139. Middle East Panic Attack Treatment, by Indicators USD Million (2019-2024)
  • Table 140. Africa Panic Attack Treatment, by Type USD Million (2019-2024)
  • Table 141. Africa Panic Attack Treatment, by Indicators USD Million (2019-2024)
  • Table 142. North America Panic Attack Treatment, by Country USD Million (2019-2024)
  • Table 143. North America Panic Attack Treatment, by Type USD Million (2019-2024)
  • Table 144. North America Panic Attack Treatment, by Indicators USD Million (2019-2024)
  • Table 145. United States Panic Attack Treatment, by Type USD Million (2019-2024)
  • Table 146. United States Panic Attack Treatment, by Indicators USD Million (2019-2024)
  • Table 147. Canada Panic Attack Treatment, by Type USD Million (2019-2024)
  • Table 148. Canada Panic Attack Treatment, by Indicators USD Million (2019-2024)
  • Table 149. Mexico Panic Attack Treatment, by Type USD Million (2019-2024)
  • Table 150. Mexico Panic Attack Treatment, by Indicators USD Million (2019-2024)
  • Table 151. Research Programs/Design for This Report
  • Table 152. Key Data Information from Secondary Sources
  • Table 153. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Panic Attack Treatment: by Type USD Million (2013-2018)
  • Figure 5. Global Panic Attack Treatment: by Indicators USD Million (2013-2018)
  • Figure 6. South America Panic Attack Treatment Share (%), by Country
  • Figure 7. Asia Pacific Panic Attack Treatment Share (%), by Country
  • Figure 8. Europe Panic Attack Treatment Share (%), by Country
  • Figure 9. MEA Panic Attack Treatment Share (%), by Country
  • Figure 10. North America Panic Attack Treatment Share (%), by Country
  • Figure 11. Global Panic Attack Treatment share by Players 2018 (%)
  • Figure 12. Global Panic Attack Treatment share by Players (Top 3) 2018(%)
  • Figure 13. Global Panic Attack Treatment share by Players (Top 5) 2018(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 16. Pfizer Inc. (United States) Revenue: by Geography 2018
  • Figure 17. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 18. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2018
  • Figure 19. Merck & Co. Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Merck & Co. Inc. (United States) Revenue: by Geography 2018
  • Figure 21. Sanofi-Aventis (France) Revenue, Net Income and Gross profit
  • Figure 22. Sanofi-Aventis (France) Revenue: by Geography 2018
  • Figure 23. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 24. AstraZeneca (United Kingdom) Revenue: by Geography 2018
  • Figure 25. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 26. Eli Lilly and Company (United States) Revenue: by Geography 2018
  • Figure 27. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 28. Johnson & Johnson (United States) Revenue: by Geography 2018
  • Figure 29. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 30. Abbott Laboratories (United States) Revenue: by Geography 2018
  • Figure 31. F-Hoffmann-La Roche (Switzerland) Revenue, Net Income and Gross profit
  • Figure 32. F-Hoffmann-La Roche (Switzerland) Revenue: by Geography 2018
  • Figure 33. Shionogi and Company (Japan) Revenue, Net Income and Gross profit
  • Figure 34. Shionogi and Company (Japan) Revenue: by Geography 2018
  • Figure 35. Global Panic Attack Treatment: by Type USD Million (2013-2018)
  • Figure 36. Global Panic Attack Treatment: by Indicators USD Million (2013-2018)
  • Figure 37. South America Panic Attack Treatment Share (%), by Country
  • Figure 38. Asia Pacific Panic Attack Treatment Share (%), by Country
  • Figure 39. Europe Panic Attack Treatment Share (%), by Country
  • Figure 40. MEA Panic Attack Treatment Share (%), by Country
  • Figure 41. North America Panic Attack Treatment Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Pfizer Inc. (United States)
  • GlaxoSmithKline (United Kingdom)
  • Merck & Co. Inc. (United States)
  • Sanofi-Aventis (France)
  • AstraZeneca (United Kingdom)
  • Eli Lilly and Company (United States)
  • Johnson & Johnson (United States)
  • Abbott Laboratories (United States)
  • F-Hoffmann-La Roche (Switzerland)
  • Shionogi and Company (Japan)
Additional players considered in the study are as follows:
Forest Laboratories Inc. (United States) , H. Lundbeck A/S (Denmark) , Allergan Plc. (Ireland) , GlaxoSmithKline Plc. (United Kingdom) , Sumitomo Dainippon Pharma Co., Ltd. (Japan) , Bristol-Myers Squibb Company (United States) , Noven Pharmaceuticals, Inc. (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation